Wednesday, June 7, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

NIH Seeking Proposals for Biodefense Research

by Global Biodefense Staff
August 20, 2014

The National Institutes of Health (NIH), in cooperation with the Centers for Disease Control and Prevention, is soliciting small business concerns for innovative research in biomedical and biodefense applications, including detection and treatment of infectious diseases.

The Small Business Innovation Research (SBIR) program provides support for research and development (R&D) of new or improved technologies and methodologies that have the potential to succeed as commercial products. SBIR legislation requires Federal agencies to reserve 2.8 percent (for FY 2014) of their extramural research or R&D budgets for an SBIR program. The NIH SBIR set-aside requirement for FY 2014 is $663 million.

Highlighted areas of interest for funding include:

  • Development of Novel Influenza Antivirals
  • Methods of Clinical Sample Preparation for Rapid Detection of Bacterial Pathogens
  • Inhaled Delivery of Clofazimine (CFZ) – An Important Anti-tuberculosis Drug
  • Simple, Inexpensive Unit for Removing Cells from Small Amounts of Blood in Resource-Limited Settings
  • Exploring the Potential of CRISPR/CAS Genome-editing Tools
  • Assay Development for High-Throughput Screening of Chemicals of Toxicological Concern
  • Diagnostic Tools to Support the Elimination and Control of Neglected Tropical Diseases
  • Development of Nanoparticle Dengue Diagnostic Tests
  • Yeast-derived Candidate of Hepatitis E Virus Vaccine
  • Multiplex Assay for Simultaneous Detection of Hepatitis and Other Viruses
  • Improved Antibody Preparation for Post-Exposure Prophylaxis Against Hepatitis A
  • Thermostable Dry Vaccine Formulation for Microneedle Administration
  • Thermostable Oral Vaccines to Combat Enteric Diseases

Further details are available under Solicitation Number: NOT-OD-14-120. The contract proposal deadline is November 5, 2014. Any small business that intends to submit an SBIR contract proposal is requested to provide early, written notice of intent per instructions in the solicitation.

Tags: AntiviralsChemical DetectionDengueNeglected Tropical DiseasesNIHThermostabilityTuberculosis

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Researcher holds a pipette
Biodetection

These Nanotech Bubbles Burst When They Detect Viruses in the Air

October 25, 2022
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC